🇺🇸 FDA

Company profile · Sponsor

Cardiol

Cardiol Therapeutics

CRDL · NYSE biotech OAKVILLE, A6, USA
Pipeline
11
Drugs
0
Patents
8

Quick answer

Cardiol (CRDL) is a biotech company. headquartered in OAKVILLE, A6, USA. listed on NYSE. NovaPharmaNews links 11 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker CRDL
Exchange NYSE
Company type biotech
Headquarters OAKVILLE, A6, USA
SEC CIK 0001702123

Pipeline (11)

Search pipeline →

  1. Cannabidiol, pharmaceutically produced with < 5 ppm THC

    Cardiol

    COVID-19

    phase 3 small molecule terminated

    1 trial

  2. CardiolRx

    Cardiol

    Recurrent Pericarditis

    phase 3 small molecule active

    2 trials

  3. CardiolRx™ Placebo is a non-aqueous solution of medium chain triglycerides with 1.0% vitamin E as anti-oxidant. CardiolRx™ Placebo is a pale yellow clear liquid. The CardiolRx™ Placebo product is essentially the same as the CardiolRx™ drug product with the exception that the placebo does not include the active drug substance, cannabidiol., CardiolRx

    Cardiol

    Recurrent Pericarditis

    phase 3 small molecule active

    1 trial

  4. Sildenafil placebo, Remidia, 20 mg, tabletki powlekane

    Cardiol

    Patients with functionally single ventricle (FSV - functionally single ventricle) after Fontan operation. The term "functionally single ventricle" refers to congenital heart defects in which one of the ventricles is not fully developed and/or one of the valves is atresia/hypoplastic as a result, it is not possible to correct the intracardiac defect. Then, there are indications for the Fontan operation, i.e. a palliative procedure - total cavo-pulmonary connection (TCPC). In patients with a functionally single ventricle, more than one operation is necessary to separate the systemic and pulmonary circulation. As a result of these procedures, Fontan circulation is created, which consists in bypassing the right heart chambers and directing the venous blood to the pulmonary artery. This leads to the removal of the right-to-left shunt and improvement of arterial blood saturation and reduction of volume overload of the systemic ventricle. At the same time, there is an increase in systemic venous pressure and a decrease in cardiac output. Low pulmonary resistance in these patients is crucial for maintaining optimal hemodynamic conditions both at rest and especially during exercise. Even a slight increase in pulmonary resistance leads to reduced pulmonary blood flow, reduced initial depression of a single ventricle, and consequently to reduced cardiac output and worsened exercise tolerance. Thus, pulmonary resistance in these patients should be not only normal, but also as low as possible to ensure adequate single ventricular filling and adequate cardiac output. There is evidence that patients with Fontan surgery increase pulmonary resistance over time. The increase in pulmonary resistance in these patients may result from several factors, and above all from the progressive dysfunction of a single systemic ventricle and the lack of a subpulmonary chamber ensuring pulsatile pulmonary flow. Although the Fontan operation in many patients with an univentricular heart is a very good method of palliative treatment, which undoubtedly extends the survival of children born with this heart defect, it also inevitably leads to severe complications developing over the years. Patients after the Fontan operation are also characterized by a significant reduction in exercise capacity, which is observed both in clinical practice in reference centres dealing with patients with congenital heart defects, and in multi-centre studies. Among other things, it was shown that children after the Fontan operation obtained 30% lower values of peak oxygen uptake in the ergospirometric test compared to the control group of healthy children (Amadero P et al., Heart 2018). The reduced exercise capacity of patients and the development of Fontan circulatory complications affect both the quality of life and the prognosis of adult patients with univentricular heart.

    phase 3 small molecule active

    1 trial

  5. Zaroxolyn 5 mg compresse, Zaroxolyn 10 mg compresse, DIAMOX 250 mg compresse

    Cardiol

    congestive heart failure

    phase 3 small molecule active

    1 trial

  6. Atorvastatina Teva Italia 80 mg compresse rivestite con film, Film-coated tablets, white, shaped elliptical, and coated with smooth film. The dimensions of each tablet are approximately 18.8 mm x 10.3 mm (identical to those containing atorvastatin).

    Cardiol

    Arrhythmogenic Cardiomyopathy (ACM)

    phase 2 small molecule active

    1 trial

  7. CardiolRx

    Cardiol

    Acute Myocarditis

    phase 2 small molecule active

    1 trial

  8. CardiolRx

    Cardiol

    Acute Myocarditis

    phase 2 small molecule completed

    1 trial

  9. Impact of CardiolRxTM on Recurrent Pericarditis: An open label Pilot Study

    Cardiol

    Recurrent Pericarditis

    phase 1 other active

    1 trial

  10. ACETYLSALICYLIC ACID , PRASUGREL , METOPROLOL , PROPRANOLOL , ATENOLOL , CARVEDILOL , CLOPIDOGREL , BISOPROLOL , TICAGRELOR

    Cardiol

    Spontaneous Coronary Artery Dissection.

    approved small molecule active

    1 trial

  11. ACETYLSALICYLIC ACID, PRASUGREL

    Cardiol

    St-Elevated Myocardial Infartion

    approved small molecule active

    1 trial

Patents (8)

Search patents →

  1. US 12419888

    Methods of treating elevated plasma cholesterol

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11844771

    Methods of treating acute respiratory distress syndrome using colchicine

    Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11795434

    Engineered stem cells and cellular products produced and secreted by such cells, methods of preparing, and uses thereof

    Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11639490

    Device and method for producing and purifying exosomes

    Expires Mon Apr 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11529390

    PCSK9 inhibitory polypolypeptides and methods of use

    Expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11400063

    Early administration of low-dose colchicine after myocardial infarction

    Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10788490

    Dried cellulose-treated tissue for in-vitro complement activation assays and diagnostic kits

    Expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9789134

    Agent for the selective adjustment of blood lipids

    Expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Cardiol?

Cardiol (CRDL) is a biotech company. headquartered in OAKVILLE, A6, USA. listed on NYSE. NovaPharmaNews links 11 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Cardiol sponsor?

We track 11 ClinicalTrials.gov-linked programs for Cardiol, including Cannabidiol, pharmaceutically produced with < 5 ppm THC and 10 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Cardiol company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.